Conghui Chen, Haiyang Hu, Mingxi Qiao, Xiuli Zhao, Yinjie Wang, Kang Chen, Xiong Guo, Dawei Chen
文献索引：Int. J. Pharm. 480(1-2) , 116-27, (2015)
全文：HTML全文
In the present study, we constructed a tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier containing paclitaxel (FA-BSA-LC/DOPE-PTX), by adding 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and oleic acid as pH-sensitive components into the formulation of lipid core and then coating with folic acid modified bovine serum albumin (FA-BSA) for tumor targeting activity. In vitro drug release study demonstrated that paclitaxel (PTX) was released from FA-BSA-LC/DOPE in a pH-dependent manner. The vitro cytotoxicity assays showed that all the blank nanocarriers were nontoxic. However, MTT assay showed that FA-BSA-LC/DOPE-PTX was highly cytotoxic. Cellular uptake experiments analyzed with flow cytometry and laser scan confocal microscope (LSCM) revealed that FA-BSA-LC/DOPE was taken up in great amount via folate receptor-mediated endocytosis and pH-sensitive release of drug to cytoplasm. Furthermore, the study of intracellular drug release behavior demonstrated that the FA-BSA-LC/DOPE escaped from lysosomes and released drug into cytoplasm. The in vivo targeting activity showed that the nanocarrier selectively targeted tumor and had long residence time for BSA layer increased the stability in blood. Moreover, FA-BSA-LC/DOPE-PTX produced very marked anti-tumor activity in tumor-bearing mice in vivo. Therefore, FA-BSA-LC/DOPE as biocompatible, tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier is a promising system for effective intracellular delivery of PTX to tumor. Copyright © 2015. Published by Elsevier B.V.
